ClinicalTrials.gg
RecruitingNCT07207122Updated Nov 19, 2026

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

An interventional study of Gen0Bh Transcranial Focused Ultrasound System (Active) and Gen0Bh Transcranial Focused Ultrasound System (Sham) in Parkinson Disease, sponsored by Sanmai Technologies PBC dba Sanmai. Recruiting at 4 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sanmai Technologies PBC dba Sanmai · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
418th of 1,257
60 · median 36
Started
2025
with 77 others
No phase
586 of 1,650
147 open now
Primary completion
2026-12
later than 100 of 384 live
Registered
1,556th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 418th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 78 that started in 2025, is one of 586 with no phase, reaches primary completion later than 100 of the 384 other live ones, and was the 1,556th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a pilot randomized, sham-controlled, double-blind, multi-center study evaluating the safety and preliminary effectiveness of the Gen0Bh Transcranial Focused Ultrasound System for the treatment of motor symptoms in individuals with idiopathic Parkinson's disease.

Read the detailed description

Participants will be randomized in a 1:1 allocation to receive either active or sham stimulation. Both participants and outcome assessors will remain blinded to treatment assignment. The study consists of 20 treatment sessions administered over approximately 4-6 weeks, followed by longitudinal follow-up through 3 months.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Low-intensity focused ultrasound neuromodulation
  • noninvasive neuromodulation
  • mild cognitive impairment
  • Parkinson disease dementia
  • PD
  • Parkinson
  • Parkinson disease
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 22 to 80 years.
  • Diagnosis of idiopathic Parkinson's disease.
  • MDS-UPDRS Part III score ≥25 in OFF-medication state at baseline.
  • Stable dopaminergic therapy for at least 30 days prior to enrollment.
  • English proficiency.
  • Normal or corrective hearing and vision.
  • Ability to provide (or availability of an LAR) and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Atypical or secondary Parkinsonism.
  • Prior deep brain stimulation or intracranial surgery.
  • score \<23.
  • Severe psychiatric illness (e.g., psychosis, suicidality, untreated major depression).
  • History of seizure or intracranial pathology.
  • Significant neurologic disease (e.g. brain tumor, multiple sclerosis)
  • to MRI or ultrasound.
  • Unstable systemic medical conditions.
  • Active or history of cancer within the past 5 years.
  • Pregnancy or breastfeeding.
  • Participation in another interventional trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Transcranial Focused Ultrasound

    Participants receive active transcranial focused ultrasound neuromodulation targeting the bilateral pallidum. Treatment consists of 20 sessions administered over approximately 4 to 6 weeks. Each session includes bilateral stimulation (15 minutes per hemisphere; 30 minutes total per session). Device parameters are configured to deliver therapeutic ultrasound energy per protocol specifications.

    Device: Gen0Bh Transcranial Focused Ultrasound System (Active)

  • Sham comparator
    Sham Transcranial Focused Ultrasound

    Participants undergo procedures identical to the active arm, including device setup, session duration, and visit schedule; however, no therapeutic ultrasound energy is delivered or energy is delivered at sub-therapeutic levels insufficient to produce neuromodulatory effects. This arm is designed to maintain participant and assessor blinding.

    Device: Gen0Bh Transcranial Focused Ultrasound System (Sham)

Interventions

  • DeviceGen0Bh Transcranial Focused Ultrasound System (Active)

    The investigational Gen0Bh system delivers noninvasive, transcranial focused ultrasound to modulate neural activity in the bilateral globus pallidus. Stimulation parameters, including frequency, intensity, and duty cycle, are pre-specified and controlled by the device software. Treatments are administered by trained study personnel in a clinical setting over 20 sessions across approximately 4 to 6 weeks.

  • DeviceGen0Bh Transcranial Focused Ultrasound System (Sham)

    The sham configuration uses the same device platform and mimics all procedural aspects of active treatment, including acoustic coupling, device setup, and session duration, without delivering therapeutic ultrasound energy to the target region. This approach is designed to maintain participant and assessor blinding.

06

What researchers measure

Primary outcomes

  1. Change in MDS-UPDRS Part III Total Score (OFF Medication State)

    The MDS-UPDRS Part III is a clinician-administered assessment of motor function in Parkinson's disease. It includes 18 items with 33 individual ratings, each scored from 0 (normal) to 4 (severe), with a total score range of 0 to 132. Higher scores indicate worse motor impairment. Assessments will be conducted in the OFF-medication state by trained, blinded raters using standardized procedures. The outcome measure is defined as the change from baseline in total score at post-treatment milestones (after Sessions 5, 10, 15, and 20), comparing active versus sham groups.

    Time frame: Baseline up to 6 weeks

  2. Incidence of Serious Adverse Device Events (SADEs)

    Number and proportion of participants experiencing Serious Adverse Device Events (SADEs), including severity and relationship to the investigational device, assessed from baseline through completion of 20 treatment sessions.

    Time frame: Baseline up to 6 weeks

Secondary outcomes

  1. Motor Function Assessments

    Finger Tapping Test - Change from baseline in tapping speed and amplitude. * 10-Meter Timed Walk Test - Change from baseline in time required to walk 10 meters. * Archimedean Spiral Test - Change from baseline in tremor severity based on spiral drawing performance. * Timed Up and Go (TUG) - Change from baseline in time required to stand, walk, turn, and sit.

    Time frame: Baseline up to 6 weeks

  2. Patient- and Clinician-Reported Outcomes

    PDQ-39 - Change from baseline in quality of life. * PGIC - Participant-reported overall improvement. * CGIC - Clinician-rated overall improvement.

    Time frame: Baseline through Month 3

  3. Psychiatric and Non-Motor Outcomes

    GAD-7 - Change from baseline in anxiety symptoms. . Beck Depression Inventory - Change from baseline in depressive symptoms.

    Time frame: Baseline through Month 3

07

Study locations

4 of 4 sites recruiting
  • University of Arizona
    Tucson, Arizona 85719, United States
    Recruiting
  • The Regenesis Project
    Santa Monica, California 90403, United States
    Recruiting
  • UF - McKnight Brain Institute
    Gainesville, Florida 32610, United States
    Recruiting
  • Radial Midtown Manhattan
    New York, New York 10018, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Radial Midtown Manhattan · New York, United StatesContact a•••@meetradial.com→r•••@meetradial.comContact a•••@meetradial.com→r•••@meetradial.com
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Radial Midtown Manhattan · New York, United StatesContact a•••@meetradial.com→r•••@meetradial.comContact a•••@meetradial.com→r•••@meetradial.com
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207122
Lead sponsor
Sanmai Technologies PBC dba Sanmai
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Oct 8, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

Clinical Team
Contact
clinical@sanm.ai
408-455-3817

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion